CRUK Oxford Centre
  • Home
  • About
    • Vision & Strategy
    • Governance
    • Membership
    • The Oxford Team
  • Research & Researchers
    • Oxford’s Cancer Researchers
    • Research Showcase
      • Cancer Big Data
      • Early Detection
      • Engineering Better Outcomes
      • Digestive Tract Cancer
      • Immunity, Infection and Inflammation
      • Blood Cancers
    • Networks & Consortia
      • Oxford Lymphoid Disorders Study Group
      • Advanced Radiotherapy Technologies Network
      • Cellular-Molecular Pathology
      • PathLAKE
      • S:CORT
      • ACRCelerate
      • EHNBPCCG
      • EPIC
      • Southampton Immune Accelerator
      • Marseille-Oxford Collaboration
      • NCIMI
      • Sichuan University (West China Hospital)-Oxford University Gastrointestinal Cancer Centre
      • PancrImmune
    • Clinical Studies
      • NuTide 301
      • TARDOX
  • Centre Support
    • Funding Opportunities
      • Development Fund
        • Previous Awards
      • CRUK Funding Calls
      • Other Funding Calls
    • Clinical Positioning Services
    • Translational Histopathology Laboratory
      • Multi-plex Immunofluorescence (IF) Imaging
      • RNAscope®
      • TMA Construction
      • Slide Scanning, Automated Tissue Segmentation and Scoring
      • Single and Double Antibody Tissue Staining (Chromogenic IHC)
      • Antibody Optimisation
      • Hematoxylin & Eosin (H&E) Staining
      • Tissue Processing, Embedding and Sectioning
    • Oxford Molecular Diagnostics Centre
    • Patient & Public Involvement in Research
    • Public Engagement
    • Informatics Tools
    • Sample Collection
    • Clinical Trial Support
    • Branding Toolkit
  • Oxford Cancer Academy
    • DPhil in Cancer Science Programme
      • Non-clinician DPhil Studentships
      • Clinical DPhil Studentships & Fellowships
      • Alumni destinations
  • News
  • Events
    • Annual Symposium
  • Contact
    • Contact us
    • Locate the Centre
  • Search
Other workshops

Pioneering Early Phase Clinical Trials

Harnessing world leading science to cure cancer

Find out more about us
DDDD
Collaboration across the Oxford Cancer Network

Translating Oxford’s World-leading Science 

  • The Oxford Centre for Drug Delivery Devices (OxCD3) is at the forefront of exploiting physical mechanisms triggered by ultrasound, magnetic fields or shock waves, to improve the delivery and penetration of drugs into tumours.
  • OxCD3 has joined forces with IBME (Institute for Biomedical Engineering), and the NIHR Oxford Biomedical Research Centre, launching the TARDOX trial.
  • Taking advantage of CRUK funded Oxford clinical trials infrastructure and the Oxford Cancer Network to develop and refine technology for patient benefit.

“Reaching therapeutic levels of cancer drugs within a tumour, while avoiding side effects for the rest of the body is a challenge for all cancer drugs, including small molecules, antibodies and viruses,” Professor Constantin Coussios, IBME, OxCD3

Device-Enhanced Drug Delivery for the Benefit of Patients

  • Aims to demonstrate that targeted mild hyperthermia, induced by focused ultrasound, can enable highly targeted/non-invasive drug delivery.
  • Uses ThermoDox® technology that improves doxorubicin efficacy.
  • LTSLs (Lysolipid thermally sensitive liposomes) hold doxorubicin but undergo structural changes releasing the chemotherapy agent at 40⁰C.
  • Shown in animal models to deliver 25x more doxorubicin than intravenous infusion, 5x more than other liposomal forms.

Results

  • After focused ultrasound intramoural biopsy doxorubicin concentrations increased by 3.7x on average
  • Treatment modality appears feasible, safe, and can enhance drug delivery
  • Demonstrating that non-invasive and inexpensive temperature monitoring using computational planning models enable effective drug delivery, this study has the potential to expand LSTL use
  • Potential to deliver patient survival benefit for a range of solid tumours.
  • Follow up studies already in the pipeline

Publications

  1. Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial. Radiology.
  2. Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase I trial. Lancet Oncology. 
  3. Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours. J Ther Ultrasound.

“This trial offers strong evidence of the rapidly evolving role of radiology in not only diagnosing disease but also guiding and monitoring therapy.” Prof. Fergus Gleeson

A single-site, open-label, phase I trial

  • Targeting primary or secondary liver tumours, unresectable and non-ablatable
  • 10 patients enrolled
  • Mean age, 60 years

People

Prof. Constantin Coussios 

Prof. Fergus Gleeson 

Prof. Mark Middleton 

In the Press

Focused ultrasound releases cancer drugs on target

  • Clinical Studies
    • NuTide 301
    • TARDOX
  • Networks & Consortia
    • ACRCelerate
    • Advanced Radiotherapy Technologies Network
    • Cellular-Molecular Pathology
    • EHNBPCCG
    • EPIC
    • Marseille-Oxford Collaboration
    • NCIMI
    • Oxford Lymphoid Disorders Study Group
    • PancrImmune
    • PathLAKE
    • S:CORT
    • Sichuan University (West China Hospital)-Oxford University Gastrointestinal Cancer Centre
      • Collaboration Projects
    • Southampton Immune Accelerator
  • Oxford’s Cancer Researchers
  • Research Showcase
    • Blood Cancers
    • Cancer Big Data
    • Digestive Tract Cancer
    • Early Detection
    • Engineering Better Outcomes
    • Immunity, Infection and Inflammation

Quick Links

  • Home
  • About
  • Research
  • Funding
  • Graduate studies
  • Events
  • Engagement
  • Sitemap
  • Privacy
  • Terms
  • Cookies
  • Branding Toolkit
  • LATEST NEWS

    • Bowel cancer patients going undiagnosed due to COVID distruptionJanuary 15, 2021 - 10:47 am
    • Prof Ahmed Ahmed in his lab“The Oxford Classic” classification system uncovers new information about ovarian cancersJanuary 14, 2021 - 8:05 am
    • Oxford spin out financed $6.8m for research into oncolytic therapiesJanuary 7, 2021 - 5:13 pm

    CONTACT

    You can keep in touch in a number of ways:

    • Visit the contact page
    • Tel: 01865 617043
    • cancercentre@oncology.ox.ac.uk
    • View the locate Centre page
    Followon TwitterSubscribeto RSS Feed

    OUR PARTNERS

    Cancer Research UK

    University Of Oxford

    Oxford University Hospitals NHS Trust

    © Copyright 2016 - CRUK Oxford Centre - Web design by Arnie
    Scroll to top